Avalo Therapeutics Appoints New Chief Medical Officer
Ticker: AVTX · Form: 8-K · Filed: Sep 4, 2024 · CIK: 1534120
| Field | Detail |
|---|---|
| Company | Avalo Therapeutics, INC. (AVTX) |
| Form Type | 8-K |
| Filed Date | Sep 4, 2024 |
| Risk Level | medium |
| Pages | 2 |
| Reading Time | 2 min |
| Key Dollar Amounts | $0.001, $35 million, $2,500,000 |
| Sentiment | neutral |
Sentiment: neutral
Topics: executive-appointment, personnel
Related Tickers: AVTX
TL;DR
AVTX just hired a new CMO with big pharma experience. Big moves coming?
AI Summary
On September 3, 2024, Avalo Therapeutics, Inc. (AVTX) announced the appointment of Dr. David E.I. Cromwell as Chief Medical Officer. Dr. Cromwell brings extensive experience in clinical development and regulatory affairs, having previously held leadership roles at companies like Merck and Pfizer.
Why It Matters
The appointment of a new Chief Medical Officer is a significant event for a biotechnology company, potentially signaling a shift in strategic direction or an acceleration of drug development programs.
Risk Assessment
Risk Level: medium — The appointment of a new executive can introduce uncertainty regarding future strategy and execution, but also brings potential for positive development.
Key Players & Entities
- Avalo Therapeutics, Inc. (company) — Registrant
- Dr. David E.I. Cromwell (person) — Newly appointed Chief Medical Officer
- Merck (company) — Previous employer of Dr. Cromwell
- Pfizer (company) — Previous employer of Dr. Cromwell
- AVTX (company) — Ticker symbol for Avalo Therapeutics, Inc.
FAQ
What is the effective date of Dr. Cromwell's appointment as Chief Medical Officer?
The filing does not explicitly state the effective date of Dr. Cromwell's appointment, but the report is dated September 3, 2024, indicating the event occurred on or before this date.
What specific experience does Dr. Cromwell bring to Avalo Therapeutics?
Dr. Cromwell has extensive experience in clinical development and regulatory affairs, with prior leadership roles at Merck and Pfizer.
What is Avalo Therapeutics' primary business focus?
Avalo Therapeutics, Inc. is in the Pharmaceutical Preparations industry, as indicated by its SIC code [2834].
Has Avalo Therapeutics undergone any previous name changes?
Yes, Avalo Therapeutics, Inc. was formerly known as Cerecor Inc., with a name change date of November 2, 2011.
Where is Avalo Therapeutics headquartered?
Avalo Therapeutics, Inc. is headquartered at 540 Gaither Road, Suite 400, Rockville, Maryland 20850.
Filing Stats: 501 words · 2 min read · ~2 pages · Grade level 14.2 · Accepted 2024-09-04 07:01:31
Key Financial Figures
- $0.001 — ange on which registered Common Stock, $0.001 Par Value AVTX Nasdaq Capital Market
- $35 million — ny's listed securities had exceeded the $35 million requirement for ten consecutive trading
- $2,500,000 — ause it failed to maintain a minimum of $2,500,000 in stockholders' equity in its Form 10-
Filing Documents
- avtx-20240903.htm (8-K) — 23KB
- 0001628280-24-039221.txt ( ) — 140KB
- avtx-20240903.xsd (EX-101.SCH) — 2KB
- avtx-20240903_lab.xml (EX-101.LAB) — 21KB
- avtx-20240903_pre.xml (EX-101.PRE) — 12KB
- avtx-20240903_htm.xml (XML) — 3KB
01 Other Events
Item 8.01 Other Events. On September 3, 2024, Avalo Therapeutics, Inc. (the "Company") received written notification from the Nasdaq Stock Market LLC ("Nasdaq") confirming that its market value of the Company's listed securities had exceeded the $35 million requirement for ten consecutive trading days, and that as a result the Company had regained compliance with Nasdaq Listing Rule 5550(b)(2) (the "Market Value of Listed Securities Standard") and the matter was now closed. As previously disclosed, on May 20, 2024, the Company received a notice (the "Notice") from the Listing Qualifications Department (the "Staff") of Nasdaq informing the Company that it no longer complied with the Nasdaq listing Rule 5550(b)(1) (the "Stockholders' Equity Requirement") because it failed to maintain a minimum of $2,500,000 in stockholders' equity in its Form 10-Q for the period ended March 31, 2024, and, as of the date of the Notice, the Company did not meet the alternatives of the Market Value of Listed Securities Standard or net income from continuing operations. 1 SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. AVALO THERAPEUTICS, INC. Date: September 4, 2024 By: /s/ Christopher Sullivan Christopher Sullivan Chief Financial Officer 2